Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma

A University of Arizona and Southwest Oncology Group study

Frederick R Ahmann, F. L. Meyskens, S. E. Jones, R. M. Bukowski, J. H. Saiers, D. H. Ryan, J. Costanzi, C. B. Vaughn, C. A. Coltman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A phase II trial was conducted to determine the clinical activity of amsacrine (m-AMSA) in patients with heavily pretreated solid tumors, myeloma, and lymphoma at the University of Arizona Cancer Center. Additionally, m-AMSA was evaluated at other Southwest Oncology Group institutions in breast cancer, myeloma, melanoma, and oat cell cancer of the lung. At a dose of 120 mg/m2 given iv every 28 days, 12 partial responses were observed in 221 patients evaluable for response. Some antitumor activity was observed in breast cancer (four responses of 65 patients), non-Hodgkin's lymphoma (three of nine), Hodgkin's disease (two of five), and sarcoma (two of 15). A partial response was also documented in one of two patients with cervical cancer. Among the 135 patients treated at the University of Arizona who were extensively evaluated for toxic effects, only myelosuppression and anemia were seen in a significant number of patients. At this dose and schedule, 29% of patients developed leukopenia of < 3000 cells/mm3, 16% developed a thrombocytopenia of < 100,000 cells/mm3, and 29% had an acute fall in hemoglobin of ≥ 2 g/100 ml. In addition, two patients suffered grand mal seizures which were not clearly drug-related. These results suggest that further study of m-AMSA in lymphoma, sarcoma, and cervical cancer is warranted.

Original languageEnglish (US)
Pages (from-to)697-700
Number of pages4
JournalCancer Treatment Reports
Volume67
Issue number7-8
StatePublished - 1983

Fingerprint

Amsacrine
Lymphoma
Neoplasms
Uterine Cervical Neoplasms
Sarcoma
Breast Neoplasms
Poisons
Small Cell Lung Carcinoma
Leukopenia
Hodgkin Disease
Thrombocytopenia
Non-Hodgkin's Lymphoma
Anemia
Melanoma
Appointments and Schedules
Hemoglobins
Seizures

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ahmann, F. R., Meyskens, F. L., Jones, S. E., Bukowski, R. M., Saiers, J. H., Ryan, D. H., ... Coltman, C. A. (1983). Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study. Cancer Treatment Reports, 67(7-8), 697-700.

Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma : A University of Arizona and Southwest Oncology Group study. / Ahmann, Frederick R; Meyskens, F. L.; Jones, S. E.; Bukowski, R. M.; Saiers, J. H.; Ryan, D. H.; Costanzi, J.; Vaughn, C. B.; Coltman, C. A.

In: Cancer Treatment Reports, Vol. 67, No. 7-8, 1983, p. 697-700.

Research output: Contribution to journalArticle

Ahmann, FR, Meyskens, FL, Jones, SE, Bukowski, RM, Saiers, JH, Ryan, DH, Costanzi, J, Vaughn, CB & Coltman, CA 1983, 'Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study', Cancer Treatment Reports, vol. 67, no. 7-8, pp. 697-700.
Ahmann, Frederick R ; Meyskens, F. L. ; Jones, S. E. ; Bukowski, R. M. ; Saiers, J. H. ; Ryan, D. H. ; Costanzi, J. ; Vaughn, C. B. ; Coltman, C. A. / Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma : A University of Arizona and Southwest Oncology Group study. In: Cancer Treatment Reports. 1983 ; Vol. 67, No. 7-8. pp. 697-700.
@article{083fcf81625e4a46a7a128c6ab3f39c4,
title = "Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study",
abstract = "A phase II trial was conducted to determine the clinical activity of amsacrine (m-AMSA) in patients with heavily pretreated solid tumors, myeloma, and lymphoma at the University of Arizona Cancer Center. Additionally, m-AMSA was evaluated at other Southwest Oncology Group institutions in breast cancer, myeloma, melanoma, and oat cell cancer of the lung. At a dose of 120 mg/m2 given iv every 28 days, 12 partial responses were observed in 221 patients evaluable for response. Some antitumor activity was observed in breast cancer (four responses of 65 patients), non-Hodgkin's lymphoma (three of nine), Hodgkin's disease (two of five), and sarcoma (two of 15). A partial response was also documented in one of two patients with cervical cancer. Among the 135 patients treated at the University of Arizona who were extensively evaluated for toxic effects, only myelosuppression and anemia were seen in a significant number of patients. At this dose and schedule, 29{\%} of patients developed leukopenia of < 3000 cells/mm3, 16{\%} developed a thrombocytopenia of < 100,000 cells/mm3, and 29{\%} had an acute fall in hemoglobin of ≥ 2 g/100 ml. In addition, two patients suffered grand mal seizures which were not clearly drug-related. These results suggest that further study of m-AMSA in lymphoma, sarcoma, and cervical cancer is warranted.",
author = "Ahmann, {Frederick R} and Meyskens, {F. L.} and Jones, {S. E.} and Bukowski, {R. M.} and Saiers, {J. H.} and Ryan, {D. H.} and J. Costanzi and Vaughn, {C. B.} and Coltman, {C. A.}",
year = "1983",
language = "English (US)",
volume = "67",
pages = "697--700",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7-8",

}

TY - JOUR

T1 - Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma

T2 - A University of Arizona and Southwest Oncology Group study

AU - Ahmann, Frederick R

AU - Meyskens, F. L.

AU - Jones, S. E.

AU - Bukowski, R. M.

AU - Saiers, J. H.

AU - Ryan, D. H.

AU - Costanzi, J.

AU - Vaughn, C. B.

AU - Coltman, C. A.

PY - 1983

Y1 - 1983

N2 - A phase II trial was conducted to determine the clinical activity of amsacrine (m-AMSA) in patients with heavily pretreated solid tumors, myeloma, and lymphoma at the University of Arizona Cancer Center. Additionally, m-AMSA was evaluated at other Southwest Oncology Group institutions in breast cancer, myeloma, melanoma, and oat cell cancer of the lung. At a dose of 120 mg/m2 given iv every 28 days, 12 partial responses were observed in 221 patients evaluable for response. Some antitumor activity was observed in breast cancer (four responses of 65 patients), non-Hodgkin's lymphoma (three of nine), Hodgkin's disease (two of five), and sarcoma (two of 15). A partial response was also documented in one of two patients with cervical cancer. Among the 135 patients treated at the University of Arizona who were extensively evaluated for toxic effects, only myelosuppression and anemia were seen in a significant number of patients. At this dose and schedule, 29% of patients developed leukopenia of < 3000 cells/mm3, 16% developed a thrombocytopenia of < 100,000 cells/mm3, and 29% had an acute fall in hemoglobin of ≥ 2 g/100 ml. In addition, two patients suffered grand mal seizures which were not clearly drug-related. These results suggest that further study of m-AMSA in lymphoma, sarcoma, and cervical cancer is warranted.

AB - A phase II trial was conducted to determine the clinical activity of amsacrine (m-AMSA) in patients with heavily pretreated solid tumors, myeloma, and lymphoma at the University of Arizona Cancer Center. Additionally, m-AMSA was evaluated at other Southwest Oncology Group institutions in breast cancer, myeloma, melanoma, and oat cell cancer of the lung. At a dose of 120 mg/m2 given iv every 28 days, 12 partial responses were observed in 221 patients evaluable for response. Some antitumor activity was observed in breast cancer (four responses of 65 patients), non-Hodgkin's lymphoma (three of nine), Hodgkin's disease (two of five), and sarcoma (two of 15). A partial response was also documented in one of two patients with cervical cancer. Among the 135 patients treated at the University of Arizona who were extensively evaluated for toxic effects, only myelosuppression and anemia were seen in a significant number of patients. At this dose and schedule, 29% of patients developed leukopenia of < 3000 cells/mm3, 16% developed a thrombocytopenia of < 100,000 cells/mm3, and 29% had an acute fall in hemoglobin of ≥ 2 g/100 ml. In addition, two patients suffered grand mal seizures which were not clearly drug-related. These results suggest that further study of m-AMSA in lymphoma, sarcoma, and cervical cancer is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0020634607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020634607&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 697

EP - 700

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7-8

ER -